Careers at Karuna
Karuna is a clinical-stage drug development company targeting muscarinic receptors for the treatment of central nervous system (CNS) disorders. Karuna initiated a Phase 2 clinical trial in schizophrenia in 2018 with its lead program, KarXT. KarXT is a product candidate consisting of xanomeline, a novel muscarinic acetylcholine receptor agonist that has demonstrated efficacy in placebo-controlled human trials in schizophrenia and Alzheimer’s disease, and trospium chloride, an FDA-approved and well-established muscarinic receptor antagonist that has been shown not to enter the CNS. Cholinergic side effects limited xanomeline development and Karuna has demonstrated an improvement in xanomeline tolerability through the addition of trospium in healthy volunteers, enabling the development of KarXT as an antipsychotic and procognitive agent.
We are looking for dynamic team members for a variety of roles. Check back often to see if a career at Karuna is right for you.